Small cell lung cancer: Will recent progress lead to improved outcomes?

Clinical Cancer Research

Volumn 21, Issue 10, 2015, Pages 2244-2255

  Pietanza, M Catherine ^a   Byers, Lauren Averett ^b   Minna, John D ^c   Rudin, Charles M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CIXUTUMUMAB; DESIPRAMINE; ERDAFITINIB; ETOPOSIDE; EVEROLIMUS; GAMMA INTERFERON; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; MARIMASTAT; MITUMOMAB; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; PLATINUM COMPLEX; SORAFENIB; SUNITINIB; TANOMASTAT; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; TOPOTECAN; UNINDEXED DRUG; VANDETANIB; VISMODEGIB; ANTINEOPLASTIC AGENT;

ARTICLE; BIOINFORMATICS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS DEVELOPMENT; DISEASE MODEL; DRUG SCREENING; EARLY DIAGNOSIS; ENDOSCOPIC BIOPSY; FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ENGINEERING; HUMAN; LUNG CARCINOGENESIS; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMALL CELL LUNG CANCER; THORAX RADIOGRAPHY; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; ANIMAL; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; SMALL CELL LUNG CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84941986957     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2958     Document Type: Article

References (138)

1. American Cancer Society. Cancer facts and figures 2014 [PDF on the Internet]. Atlanta, GA: American Cancer Society; 2014 [cited 2015 Feb 8]. Report No.: 500814. Available from: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf.
2. Gaspar LE, McNamara EJ,Gay EG, Putnam JB, Crawford J, Herbst RS, et al. Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer 2012;13:115-22.
3. Varghese AM, Zakowski MF, Yu HA, Won HH, Riely GJ, Krug LM, et al. Small-cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol 2014;9:892-6.
4. Ou SH, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol 2009; 4:37-43.
5. Amini A, Byers LA, Welsh JW, Komaki RU. Progress in the management of limited-stage small cell lung cancer. Cancer 2014;120:790-8.
6. Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-Analysis. J Clin Oncol 2006;24:3823-30.
7. Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. JClin Oncol 2004;22:4837-45.
8. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, Minken A, Wanders R, Lutgens L, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006; 24:1057-63.
9. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P, et al. Systematic review and meta-Analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006;17: 543-52.
10. Pijls-Johannesma MC, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 2005;(1):CD004700.
11. Huncharek M, McGarry R. A meta-Analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist 2004;9:665-72.
12. Turrisi AT, 3rd,Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71.
13. Auperin A, Arriagada R, Pignon J, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999;341:476-84.
14. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer.NEngl J Med 2007;357:664-72.
15. Simon GR, Turrisi A, American College of Chest P. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:324S-39S.
16. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67.
17. O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7.
18. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25: 2086-92.
19. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-09.
20. Higgins GA, Shields TW, Keehn RJ. The solitary pulmonary nodule. Tenyear follow-up of Veterans Administration-Armed Forces Cooperative Study. Arch Surg 1975;110:570-5.
21. Quoix E, Fraser R, Wolkove N, Finkelstein H, Kreisman H. Small cell lung cancer presenting as a solitary pulmonary nodule. Cancer 1990;66: 577-82.
22. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489: 519-25.
23. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
24. National Cancer Institute. Scientific framework for small cell lung cancer (SCLC) [PDF on the Internet]. Bethesda (MD): National Cancer Institute; 2014 [cited 2015 Feb 8]. Available from: http://deainfo.nci.nih.gov/advisory/ctac/workgroup/SCLC/SCLC%20Congressional%20Response. pdf.
25. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010;463:184-90.
26. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012;44:1111-6.
27. Peifer M, Fernandez-Cuesta L, SosML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104-10.
28. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature 2013;499:214-8.
29. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001;28:3-13.
30. Mori N, Yokota J, Akiyama T, Sameshima Y, Okamoto A, Mizoguchi H, et al. Variable mutations of the RB gene in small-cell lung carcinoma. Oncogene 1990;5:1713-7.
31. Arriola E, Canadas I, Arumi M, Rojo F, Rovira A, Albanell J. Genetic changes in small cell lung carcinoma. Clinic Transl Oncol 2008;10: 189-97.
32. Riely GJ, Yu HA. EGFR: the paradigm of an oncogene-driven lung cancer. Clin Cancer Res 2015;21:2221-6.
33. Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 2015;21:2227-35.
34. Gazdar AF, Savage TK, Johnson JE, Berns A, Sage J, Linnoila RI, et al. The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol 2015;10:553-64.
35. McFadden DG, Papagiannakopoulos T, Taylor-Weiner A, Stewart C, Carter SL, Cibulskis K, et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 2014;156:1298-311.
36. Cui M, Augert A, Rongione M, Conkrite K, Parazzoli S, Nikitin AY, et al. PTEN is a potent suppressor of small cell lung cancer. Mol Cancer Res 2014;12:654-9.
37. Jahchan NS, Dudley JT,Mazur PK, Flores N, Yang D, Palmerton A, et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 2013;3:1364-77.
38. Baetscher M, Schmidt E, Shimizu A, Leder P, Fishman MC. SV40 T antigen transforms calcitonin cells of the thyroid but not CGRP-containing neurons in transgenic mice. Oncogene 1991;6:1133-8.
39. Magdaleno SM, Wang G, Mireles VL, Ray MK, Finegold MJ, DeMayo FJ. Cyclin-dependent kinase inhibitor expression in pulmonary Clara cells transformed with SV40 large T antigen in transgenic mice. Cell Growth Differ 1997;8:145-55.
40. Kwak I, Tsai SY, DeMayo FJ. Genetically engineered mouse models for lung cancer. Annu Rev Physiol 2004;66:647-63.
41. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003;4: 181-9.
42. Song H, Yao E, Lin C, Gacayan R, Chen MH, Chuang PT. Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. Proc Natl Acad Sci U S A 2012;109: 17531-6.
43. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011;19:754-64.
44. Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL, et al. Loss of p130 accelerates tumor development in a mouse model for human smallcell lung carcinoma. Cancer Res 2010;70:3877-83.
45. Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN,Mahjoub MR, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med 2011;17:1504-08.
46. Calbo J, van Montfort E, Proost N, van Drunen E, Beverloo HB, Meuwissen R, et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 2011;19:244-56.
47. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 2009;69:3364-73.
48. Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nature Med 2014;20:897-903.
49. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012;2:798-811.
50. Teicher BA. Perspective: Opportunities in recalcitrant, rare and neglected tumors. Oncol Rep 2013;30:1030-4.
51. Wang J, Byers LA. Teaching an old dog new tricks: drug repositioning in small cell lung cancer. Cancer Discov 2013;3:1333-5.
52. Hwang DH, Sun H, Rodig SJ, Hornick JL, Sholl LM. Myc protein expression correlates with MYC amplification in small-cell lung carcinoma. Histopathology 2014 Nov 19. [Epub ahead of print].
53. Rudin CM, Poirier JT. MYC, MAX, and small cell lung cancer. Cancer Discov 2014;4:273-4.
54. SosML, Dietlein F, Peifer M, Schottle J, Balke-WantH, Muller C, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci U S A 2012;109: 17034-9.
55. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011;108:16669-74.
56. Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, et al. Small molecule inhibitors of aurora-A induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell 2013;24:75-89.
57. den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 2010;116:1498-505.
58. Lu LY, Wood JL, Ye L, Minter-Dykhouse K, Saunders TL, Yu X, et al. Aurora A is essential for early embryonic development and tumor suppression. J Biol Chem 2008;283:31785-90.
59. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008;1786:60-72.
60. Hook KE, Garza SJ, Lira ME, Ching KA, Lee NV, Cao J, et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther 2012;11:710-9.
61. Melichar B, Adenis A, Havel L, Lockhart AC, Bennouna J, Schusterbauer C, et al. Phase (Ph) I/II study of investigational Aurora A kinase (AAK) inhibitorMLN8237 (alisertib): updated ph II results in patients (pts) with small cell lung cancer (SCLC), non-SCLC (NSCLC), breast cancer (BrC), head and neck squamous cell carcinoma (HNSCC), and gastroesophageal cancer (GE). J Clin Oncol 31, 2013 (suppl; abstr 605).
62. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92.
63. Gregory PD, Wagner K, Horz W. Histone acetylation and chromatin remodeling. Exp Cell Res 2001;265:195-202.
64. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27:5459-68.
65. Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther 2009;8:3075-87.
66. Luchenko VL, Salcido CD, Zhang Y, Agama K, Komlodi-Pasztor E, Murphy RF, et al. Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle 2011; 10:3119-28.
67. Romanski A, Schwarz K, Keller M, Wietbrauk S, Vogel A, Roos J, et al. Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. Cell Cycle 2012;11: 3219-26.
68. Xu Y, Voelter-Mahlknecht S, Mahlknecht U. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-Abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. Int J Mol Med 2005;15:169-72.
69. Seo SK, Jin HO, Woo SH, Kim YS, An S, Lee JH, et al. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation. J Thorac Oncol 2011;6:1313-9.
70. Esteller M, Herman JG. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004;23:1-8.
71. Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001; 1:61-7.
72. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20:2388-99.
73. Kalemkerian GP, Loo BW, Akerley W, Bogner P, Chow LQM, Doebele RC, et al.NCCNclinical practice guidelines in oncology: small cell lung cancer version I. 2015 [PDF on the Internet]. Fort Washington, PA: National Comprehensive Cancer Network; 2015 [cited 2015 Jan 22]. Available from: http://www.nccn.org/professionals/physician-gls/pdf/sclc.pdf.
74. Cardnell RJ, Feng Y, Diao L, Fan Y-H, Masrorpour F, Wang J, et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res 2013;19:6322-8.
75. Wainberg ZA, Rafii S, Ramanathan RK,Mina LA, Byers LA, Chugh R, et al. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients. J Clin Oncol 32:5s, 2014 (suppl; abstr 7522).
76. Liu H, Kho AT, Kohane IS, Sun Y. Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development. PLoS Med 2006;3:e232.
77. Park KS,Martelotto LG, Peifer M, Sos ML, Karnezis AN,Mahjoub MR, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nature Med 2011;17:1504-8.
78. Peacock CD, Watkins DN. Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol 2008;26:2883-9.
79. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003;3:895-902.
80. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006;5:1026-33.
81. Malik B, Nie D. Cancer stem cells and resistance to chemo and radio therapy. Front Biosci (Elite Ed) 2012;4:2142-9.
82. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012;12:133-43.
83. Belani CP, Dahlberg SE, Rudin CM, FleisherM, Chen HX, Takebe N, et al. Three-Arm randomized phase II study of cisplatin and etoposide versus cisplatine and etoposide with either vismodegib or cixutumumab for patients with extensive stage-small cell lung cancer (ECOG 1508). J Clin Oncol 31, 2013 (suppl; abstract 7508).
84. Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 2014;141:140-9.
85. Yen W-C, Fischer MM, Axelrod F, Bond C, Cain J, Cancilla B, et al. Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res 2015;21:2084-95.
86. Borges M, Linnoila RI, vande Velde HJ, Chen H, Nelkin BD, Mabry M, et al. An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature 1997;386:852-5.
87. Jiang T, Collins BJ, Jin N, Watkins DN, Brock MV,MatsuiW, et al. Achaetescute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res 2009;69:845-54.
88. Miki M, Ball DW, Linnoila RI. Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung. Lung Cancer 2012;75:58-65.
89. Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci U S A 2014;111: 14788-93.
90. Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res 2005;65:10680-5.
91. Graus F, Dalmou J, Rene R, Tora M, Malats N, Verschuuren JJ, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997;15:2866-72.
92. Tanio Y, Watanabe M, Osaki T, Tachibana I, Kawase I, Kuritani T, et al. High sensitivity to peripheral blood lymphocytes and low HLA-class I antigen expression of small cell lung cancer cell lines with diverse chemoradiosensitivity. Jpn J Cancer Res 1992;83:736-45.
93. Yazawa T, Kamma H, Fujiwara M, Matsui M, Horiguchi H, Satoh H, et al. Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol 1999;187:191-9.
94. Koyama K, Kagamu H, Miura S, Hiura T, Miyabayashi T, Itoh R, et al. Reciprocal CD4+ T-cell balance of effector CD62LlowCD4+ and CD62LhighCD25+CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res 2008;14:6770-9.
95. Schultheis AM, Scheel AH, Ozretic L, George J, Thomas RK, Hagemann T, et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer 2015;51:421-6.
96. Soria J-C, Marabelle A, Brahmer JR, Gettinger S. Immune checkpoint modulation for non-small cell lung cancer. Clin Cancer Res 2015;21: 2256-62.
97. Hellmann M, Creelan B,WooK, Sima C, Iams W, Antonia S, et al. Smoking history and response to nivolumab in patients with advanced NSCLCs. Ann Oncol 2014;25:iv426-470.
98. Garon EB, Gandhi L, Rizvi N, Hui R, Balmanoukian AS, Patnaik A, et al. Antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand (PD-L1) expression in a pooled analysis of patients with advanced NSCLC. Ann Oncol 2014;25:v1-v41.
99. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7.
100. Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-smallcell lung cancer (CheckMate 063): a phase 2, single-Arm trial. Lancet Oncol 2015;16:257-65.
101. Gandara DR, Hammerman PS, Sos ML, Lara PN Jr, Hirsch FR. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res 2015;21:2236-43.
102. Rizvi NA, HellmanMD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348: 124-8.
103. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:2046-54.
104. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013; 24:75-83.
105. Recalcitrant Cancer Research Act of 2012, Pub. L. No. 112-176, 112 Stat. 733 (Sept 19, 2012).
106. Mattson K, Niiranen A, Pyrhonen S, Holsti LR, Holsti P, Kumpulainen E, et al. Natural interferon alfa as maintenance therapy for small cell lung cancer. Eur J Cancer 1992;28A:1387-91.
107. Prior C, Oroszy S, Oberaigner W, Schenk E, Kummer F, Aigner K, et al. Adjunctive interferon-Alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial. Eur Respir J 1997;10:392-6.
108. Ruotsalainen TM, Halme M, Tamminen K, Szopinski J, Niiranen A, Pyrhonen S, et al. Concomitant chemotherapy and IFN-Alpha for small cell lung cancer: a randomized multicenter phase III study. J Interferon Cytokine Res 1999;19:253-9.
109. Kelly K, Crowley JJ, Bunn PA Jr, Hazuka MB, Beasley K, Upchurch C, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol 1995;13: 2924-30.
110. Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, Tschetter LK, et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol 1994;12:2321-6.
111. van Zandwijk N, Groen HJ, Postmus PE, Burghouts JT, ten Velde GP, Ardizzoni A, et al. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1997;33:1759-66.
112. Clamon G, Herndon J, Perry MC, Ozer H, Kreisman H, Maher T, et al. Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. J Natl Cancer Inst 1993; 85:316-20.
113. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002;20:4434-9.
114. Rigas JR, Denham CA, Rinaldi DA, Moore TD, Smith JW, Winston RD, et al. Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor BAY12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer. J Clin Oncol 22: 2003 (suppl; abstr 2525).
115. Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM Jr,Morton RF, et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005;16:1811-6.
116. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003;9:5880-7.
117. Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, et al. Imatinibmesylate lacks activity in small cell lung carcinoma expressing ckit protein: a phase II clinical trial. Cancer 2005;103:2128-31.
118. Pandya KJ, Levy DE, Hidalgo M, Cohen RB, Lee MW, Schiller JH, et al. A randomized, phase IIECOGtrial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A preliminary report. J Clin Oncol 23:16s, 2005 (suppl; abstr 7005).
119. Tarhini A, Kotsakis A, Gooding W, Shuai Y, Petro D, Friedland D, et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 2010;16:5900-7.
120. Heymach JV, Johnson DH, Khuri FR, Safran H, Schlabach LL, Yunus F, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 2004; 15:1187-93.
121. Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, et al. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensivestage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008;26: 870-6.
122. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, et al. Phase II study of single-Agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 2012;18:3163-9.
123. Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N, et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 2011;74:481-5.
124. Langer CJ, Albert I, Kovacs P, Blakely LJ, Pajkos G, Petrov P, et al. A randomized phase II study of carboplatin and etoposide with or without pan-BCL-2 antagonist obatoclax in extensive-stage small cell lung cancer. J Clin Oncol 29: 2011 (suppl; abstr 7001).
125. Lara PN Jr, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol 2006;1:996-1001.
126. Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005;23:6854-64.
127. Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007;25:3945-51.
128. Lee SM, Woll PJ, Rudd R, Ferry D, O'Brien M, Middleton G, et al. Antiangiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009;101:1049-57.
129. Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007;25:4278-84.
130. Gitlitz BJ, Moon J, Glisson BS, Reimers HJ, Bury MJ, Floyd JD, et al. Sorafenib in platinum-treated patientswith extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol 2010;5:1835-40.
131. Ramalingam SS, Belani CP, Mack PC, Vokes EE, Longmate J, Govindan R, et al. Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol 2010; 5:1279-84.
132. Heymach J, Glisson BS, Doebele RC, Huang C, Gandara DR, Le Scouiller S, et al. Phase I open-label study of cediranib plus etoposide and cisplatin as first-line therapy for patients with small cell lung cancer or lung neuroendocrine cancer. J Clin Oncol 28:15s, 2010 (suppl; abstr 7050).
133. Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009;27: 6006-11.
134. Ready N, Dudek AZ, Wang XF, Graziano SL, Green MR, Vokes EE. CALGB 30306: A phase II study of cisplatin, irinotecan and bevacizumab for untreated extensive stage small cell lung cancer. J Clin Oncol 25: 2007 (suppl; abstr 7563).
135. Spigel DR,Greco FA, Zubkus JD,Murphy PB, Saez RA, Farley C, et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 2009;4:1555-60.
136. Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011;29:2215-22.
137. Ready N, Pang H, Gu L, Otterson GA, Thomas SP, Miller AA, et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small cell lung cancer: A randomized, double-blind, placebo controlled phase II study-CALGB 30504 (ALLIANCE). J Clin Oncol 2015 Mar 2. [Epub ahead of print].
138. DeVita VT Jr, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg's cancer: principles and practice of oncology. 10th ed. Philadelphia, PA: Wolters Kluwer; 2014.